Radiation Oncology

A total of 46.6% of patients showed a favorable response to ultrahypofractionation radiotherapy for locally advanced breast cancer.

CAR T-cell therapies and T-cell engagers may produce an “exciting” benefit on the radiosensitization of prostate tumors.

The phase 2 study aimed to compare the safety of pembrolizumab and radiation with or without olaparib in this high-risk population.

The expansion of clinical trials evaluating proton-based radiotherapy could elucidate its benefits and increase its access across the US.

Experts review strategies for effective screening and other measures for limiting cancer incidence in observance of National Cancer Prevention Month.

Jason Molitoris, MD, PhD, discussed 2025 data on proton therapy for oropharyngeal cancer, highlighting immune preservation and reduced long-term AEs.

According to Charlotte Rivers, MD, it’s important for patients with CNS cancers to meet with all involved doctors so they can make an informed decision regarding their care.

J. Isabelle Choi, MD, shared her specific fractionation preferences and prophylactic strategies to combat adverse effects associated with radiation.

Charlotte Ivy Rivers, MD, explored the impact of updated WHO criteria and functional imaging, such as DOTATATE-PET, on the diagnosis and treatment of patients with CNS tumors.

Sunil W. Dutta, MD, discussed why clinical follow-up remains an essential soft skill for radiation oncologists in an increasingly automated field.

Charlotte Ivey Rivers, MD, discussed the importance of rare CNS tumor research, upcoming trial data in meningioma, and the role of functional radiosurgery.

Fumiko Chino, MD, discussed the nuances of patient-centered care, addressing financial toxicity, AI bias in oncology, and survivorship.

Pranshu Mohindra, MD, outlined considerations for optimizing the use of hypofractionated radiation for patients with lung cancer.

Sunil W. Dutta, MD, discussed hypofractionation in breast reconstruction and why clinical follow up remains a key "soft skill" in an AI-driven field.

Emily Papai, MD, discussed her study on RECIST responses to neoadjuvant radiation in retroperitoneal sarcoma and the challenges of organ-sparing surgery.

The differences in treatment setting are associational and are likely influenced by confounding by indication and not treatment effects.

A 5-year OS rate of 97.1% was observed among patients who received PSMA PET/CT restaging at first biochemical recurrence following prostatectomy.

Parul Barry, MD, discusses advances such as ultrahypofractionated radiation and the growing role of AI in streamlining workflows for breast cancer care.

Theranostics, a technique that combines traditional medication with diagnostics, is “limitless,” according to Brandon Mancini, MD, MBA, FACRO.

Based on the prevalence of GLP-1 agonists employed in standard medical practice, Li’s team will assess their impact on radiotherapy for prostate cancer.

Theranostics is an escalating field within radiation oncology and clinicians should be utilizing it every day, according to Brandon Mancini, MD, MBA, FACRO.

J. Isabelle Choi, MD, outlined evidence-based strategies for radiation dose escalation in locoregionally advanced breast cancer.

Experts discuss new modalities such as HPV vaccines, balancing hope with realism, and other considerations in cervical cancer management.

Throughout 2026, CancerNetwork® and the journal ONCOLOGY® will be dedicated to sharing the most critical developments in the radiation oncology field.

Host Brandon Mancini, MD, MBA, FACRO, introduces a special podcast series focused on delivering key insights and takeaways in the radiation oncology space.